Integrins are a large family of cell surface receptors that are involved in
a wide range of biological processes. The integrin alpha (IIb)beta (3) (gl
ycoprotein IIb-IIIa) is a major platelet glycoprotein heterodimeric recepto
r that mediates platelet aggregation and is currently a target for pharmace
utical intervention. Ligand binding to the receptor has been shown to induc
e conformational changes by physical methods and the exposure of neoepitope
s (the ligand-induced binding sites). Here we show that the antagonist XP28
0 induces a conformation that is stable to treatment with SDS and that the
protein retains this conformation for several days even after dissociation
of the inhibitor. These ligand-induced conformational changes take place wi
th purified protein and on intact platelets. They are competable with an RG
DS peptide and are stable to reduction but not boiling or treatment with ED
TA. The retention of an altered conformation in the absence of the ligand i
mplies the possibility of ligand-induced alteration of biological function
even in the absence of ligand, Finally, similar behavior is observed with t
he integrin alpha (v)beta (3), suggesting that access to SDS stable conform
ations may be conserved throughout the integrin superfamily. The unusual st
ability, long-lived nature, and potential generality of these conformations
could have profound implications for integrin biology.